Merck Slims R&D Spend, Homes In On Best Assets Like Lambrolizumab
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck advises that R&D spend for 2013 will be a lower than 2012 as it absorbs a hit from patent expirations of major products. Company stresses that it will prioritize drugs that have potential to shake up clinical practice, like lambrolizumab in oncology and MK-8931 in Alzheimer’s disease.